Skip to main content
SpringerLink
Log in

Lentigo Maligna

Prognosis and Treatment Options

  • Therapy in Practice
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Lentigo maligna is a premalignant melanocytic neoplasm occurring on the sun-exposed skin of the middle-aged and elderly. It is believed to represent the in situ phase of lentigo maligna melanoma and, as such, cure is usually the aim of treatment. However, factors such as site and size of lesion and patient co-morbidities may influence the treatment modality undertaken. Surgical excision is the treatment of choice to obtain clinical and histologic clearance, but many other modalities have been used with variable success. Mohs micrographic surgery is associated with the lowest recurrence rate at 4–5%, but conventional surgery, cryotherapy and radiotherapy also yield good results, with recurrence rates in the order of 7–10%. Other treatments have been tried but currently there are not enough data to support their routine use. In order to make the best decision regarding appropriate management of lentigo maligna, the dermatologist or surgeon must be aware of all the options available and the evidence supporting their use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Fig. 3
Table II
Fig. 4
Table III
Table IV
Fig. 5

Similar content being viewed by others

References

  1. Farshad A, Burg G, Panizzon R, et al. A retrospective study of 150 patients with lentigo maligna and lentigo mal igna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatology. 2002; 146: 1042–6

    Article  CAS  Google Scholar 

  2. Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1995 Dec; 33 (6): 923–36

    Article  PubMed  CAS  Google Scholar 

  3. Durnick A, Stolz W, Landthaler M, et al. Lentigo maligna and lentigo maligna melanoma in young adults. Dermatol Surg. 2004; 30 (5): 813–6

    Article  PubMed  Google Scholar 

  4. Kuffk EG, Gage AA. Cryosurgery for lentigo maligna. J Am Acad Dermatol. 1994 Jul; 31 (1): 75–8

    Article  Google Scholar 

  5. Wayte DM, Helwig EB. Melanotic freckle of Hutchinson. Cancer. 1968 May; 21: 893–901

    Article  PubMed  CAS  Google Scholar 

  6. Hutchinson J. Notes on the cancerous process and on new growths in general. Arch Surg (London). 1890; 2: 83–6

    Google Scholar 

  7. Hutchinson J. On tissue dotage. Arch Surg (London). 1892; 3: 315–22

    Google Scholar 

  8. Hutchinson J. On cancer. Arch Surg (London). 1893; 4: 61–3

    Google Scholar 

  9. Hutchinson J. Lentigo melanosis: a further report. Arch Surg (London). 1894; 5: 53–6

    Google Scholar 

  10. Hutchinson J. President’s address at the Third International Congress of Dermatology. Arch Surg (London). 1896; 7: 297–317

    Google Scholar 

  11. Dubreuilh MW. Lentigo malin des vieillards. Ann Dermatol Syphiligr (Paris). 1894 Aug; 5: 1092–9

    Google Scholar 

  12. Dubreuilh MW. De la mélanose circonscrite précancéreuse. Ann Dermatol Syphiligr (Paris). 1912; 3: 129–51, 205–30

    Google Scholar 

  13. The British Association of Dermatologists and the Melanoma Study Group. UK guidelines for the management of cutaneous melanoma. Br J Dermatol. 2002; 146: 7–17

    Google Scholar 

  14. Jackson R, Williamson GS, Beattie WG. Lentigo maligna and lentigo maligna melanoma. CMAJ. 1966; 95: 846–51

    CAS  Google Scholar 

  15. Davis J, Pack GT, Higgins GK. Melanotic freckle of Hutchinson. Am J Surg. 1967; 113: 457–63

    Article  PubMed  CAS  Google Scholar 

  16. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol. 1987; 116: 303–10

    Article  PubMed  CAS  Google Scholar 

  17. Mishima Y. Melanocytic and nevocytic malignant melanomas: cellular and subcellular differentiation. Cancer. 1967; 20: 632–49

    Article  PubMed  CAS  Google Scholar 

  18. Grionspan D, Paz A, Abulafia J, et al. Melanoma (léntigo maligna de Hutchinson) de regression espontanea: caso de interés inmunólogico. Med Cután Ibero Lat Am. 1980; 8: 33–45

    Google Scholar 

  19. Coleman WP, Davis RS, Reed RJ, et al. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol. 1980 Jun; 6: 476–9

    PubMed  Google Scholar 

  20. Bartoli C, Bono A, Clemente C, et al. Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer. 1996; 77: 888–92

    Article  PubMed  CAS  Google Scholar 

  21. Clark Jr WH, Mihm Jr MC. Lentigo maligna and lentigo maligna melanoma. Am J Pathol. 1969; 55: 39–54

    PubMed  Google Scholar 

  22. Clark Jr WH, Ainsworth AM, Bernardino EA, et al. The developmental biology of primary human malignant melanomas. Semin Oncol. 1975; 2: 83–103

    PubMed  Google Scholar 

  23. Knudsen EA, Thomsen HK. Lentigo malignant melanoma. Ugeskr Laeger. 1994; 156: 4251–2

    PubMed  CAS  Google Scholar 

  24. Austin WE. Melanotic freckle as a precursor of malignant melanoma: report of a case. Can J Surg. 1963; 6: 363–6

    PubMed  CAS  Google Scholar 

  25. Costello MJ, Fisher SB, DeFeo CP. Melanotic freckle. Arch Dermatol. 1959; 80: 753–71

    Article  PubMed  CAS  Google Scholar 

  26. Koh HK, Michalik EE, Sober AJ, et al. Lentigo maligna has no better prognosis than other types of melanoma. J Clin Oncol. 1984 Sep; 2 (9): 994–1001

    PubMed  CAS  Google Scholar 

  27. Kelly JW. Following lentigo maligna may not prevent the development of lifethreatening melanoma. Arch Dermatol. 1992 Jan; 128 (5): 657–60

    Article  PubMed  CAS  Google Scholar 

  28. Albert LS, Fewkes J, Sober AJ. Metastatic lentigo maligna melanoma. J Dermatol Surg Oncol. 1990; 16: 56–8

    PubMed  CAS  Google Scholar 

  29. Michalik EE, Fitzpatrick TB, Sober AJ. Rapid progression of lentigo maligna to deeply invasive lentigo maligna melanoma: report of two cases. Arch Dermatol. 1983; 119: 831–5

    Article  PubMed  CAS  Google Scholar 

  30. Penneys NS. Microinvasive lentigo maligna melanoma. J Am Acad Dermatol. 1987 Oct; 17 (4): 675–80

    Article  PubMed  CAS  Google Scholar 

  31. Somach SC, Taira JW, Pitha JV, et al. Pigmented lesions in actinically damaged skin. Arch Dermatol. 1996; 132: 1297–302

    Article  PubMed  CAS  Google Scholar 

  32. Cohen LM, McCall MW, Zax RH. Mobs micrographic surgery for lentigo maligna melanoma: a follow up study. Dermatol Surg. 1998; 24 (6): 673–7

    Article  PubMed  CAS  Google Scholar 

  33. Carucci JA. Treatment of lentigo maligna. Cutis. 2001; 67: 389–92

    PubMed  CAS  Google Scholar 

  34. Agarwal-Antal N, Bowen BG, Gerwels JW. Histologic evaluation of lentigo maligna with permanent section: implications regarding current guidelines. J Am Acad Dermatol. 2002 Nov; 47 (5): 743–8

    Article  PubMed  Google Scholar 

  35. Grande DJ, Koranda FC, Whittaker DC. Surgery of extensive, sub-clinical lentigo maligna melanoma. J Dermatol Surg Oncol. 1982; 8: 493–6

    PubMed  CAS  Google Scholar 

  36. Johnson TM, Smith JW, Nelson BR, et al. Current therapy for cutaneous melanoma. J Am Acad Dermatol. 1995; 32: 689–707

    Article  PubMed  CAS  Google Scholar 

  37. McEwan LE, Buchanan MRC. Invasive melanoma in the donor and recipient sites of a Hutchinson’s freckle transplanted in a split skin graft. Aust N Z J Surg. 1986; 56: 81–4

    Article  PubMed  CAS  Google Scholar 

  38. Kelly RI, Cook MG, Mortimer PS. Aggressive amelanotic lentigo maligna. Br J Dermatol. 1994; 131: 562–5

    Article  PubMed  CAS  Google Scholar 

  39. Litwan MS, Kremetz ET, Mansell PW, et al. Topical chemotherapy of lentigo maligna with 5-fluorouracil. Cancer. 1975; 3: 721–33

    Article  Google Scholar 

  40. Kroumpouzos G, Frank EW, Albertini JG, et al. Lentigo maligna with spread onto oral mucosa. Arch Dermatol. 2002; 138 (9): 1216–20

    Article  PubMed  Google Scholar 

  41. Mahendran R, Newton-Bishop JA. Survey of UK current practice in the treatment of lentigo maligna. Br J Dermatol. 2001; 144: 71–6

    Article  PubMed  CAS  Google Scholar 

  42. Gasper ZS, Dawber RPR. Treatment of lentigo maligna. Australas J Dermatol. 1997; 38: 1–8

    Article  Google Scholar 

  43. Davalbhakta A, Hamilton S, Grant JW, et al. Spread of a recurrent lentigo maligna into a graft: a case for conservative treatment. Br J Plast Surg. 2001; 54 (3): 253–6

    Article  PubMed  CAS  Google Scholar 

  44. Pitman GH, Kopf AW, Bart RS, et al. Treatment of lentigo maligna melanoma. J Dermatol Surg Oncol. 1979 Sep; 5: 727–37

    PubMed  CAS  Google Scholar 

  45. Tsang RW, Liu F-F, Wells W, et al. Lentigo maligna of the head and neck. Arch Dermatol. 1994; 130: 1008–12

    Article  PubMed  CAS  Google Scholar 

  46. Marsden JR, Sanders DSA. Lentigo maligna: surgical treatment. J Fur Acad Dermatol Venereol. 1995; 5 (1001): 100–2

    Google Scholar 

  47. Bub JL, Berg D, Slee A, et al. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol. 2004; 140 (5): 552–8

    Article  PubMed  Google Scholar 

  48. Hill DC, Gramp AA. Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australas J Dermatol. 1999; 40 (1): 25–30

    Article  PubMed  CAS  Google Scholar 

  49. Robinson JK. Margin control for lentigo maligna. J Am Acad Dermatol. 1994; 31: 79–85

    Article  PubMed  CAS  Google Scholar 

  50. Montagna W, Kirchner S, Carlisle K. Histology of sun damaged skin. J Am Acad Dermatol. 1989; 21: 907–18

    Article  PubMed  CAS  Google Scholar 

  51. National Institutes of Health Consensus Conference. Diagnosis and treatment of early melanoma. JAMA. 1992; 268: 1314–9

    Article  Google Scholar 

  52. Huilgol SC, Selva D, Chen C, et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol. 2001; 140 (9): 1087–92

    Article  Google Scholar 

  53. Preston PW, Matey P, Sanders DSA, et al. Surgical treatment of lentigo maligna using 2-mm excision margins [abstract]. Br J Dermatol; 2003; 149 (64): 109–10

    Google Scholar 

  54. Dhawan SS, Wolf DJ, Rabinovitz HS, et al. Lentigo maligna: the use of rush permanent sections in therapy. Arch Dermatol. 1990; 126: 928–30

    Article  PubMed  CAS  Google Scholar 

  55. Malhotra R, Chan C, Huilgol SC, et al. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology. 2003; 110 (10): 2011–8

    Article  PubMed  Google Scholar 

  56. Abide JM, Nahai F, Bennett RG. The meaning of surgical margins. Plast Reconstr Surg. 1984; 73: 492–6

    Article  PubMed  CAS  Google Scholar 

  57. Cohen LM, McCall MW, Hodge SJ, et al. Successful treatment of lentigo maligna and lentigo maligna melanoma with Mobs’ micrographic surgery aided by rush permanent sections. Cancer. 1994 Jun; 73: 2964–70

    Article  PubMed  CAS  Google Scholar 

  58. Zitelli JA, Moy RL, Abell E. The reliability of frozen sections in the evaluation of surgical margins or melanoma. J Am Acad Dermatol. 1991; 24: 403–7

    Article  Google Scholar 

  59. Nield DV, Saad MN, Khoo CT, et al. Tumour thickness in malignant melanoma: the limitations of frozen section. Br J Plast Surg. 1988; 41: 403–7

    Article  PubMed  CAS  Google Scholar 

  60. Gross EA, Anderson WK, Rogers GS. Mobs Micrographic Excision of Lentigo Maligna Using Mel-5 for margin control. Arch Dermatol. 1999; 135: 15–7

    Article  PubMed  CAS  Google Scholar 

  61. Stonecipher MR, Leshin B, Patrick J. Management of lentigo maligna and lentigo maligna melanoma with paraffin-embedded tangential sections: utility of immunoperoxidase staining and supplemental vertical sections. J Am Acad Dermatol Oct. 1993; 29 (4): 589–94

    Article  CAS  Google Scholar 

  62. Johnson TM, Headington JT, Baker SR, et al. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: The “Square” procedure. J Am Acad Dermatol. 1997 Nov; 37 (5): 758–64

    Article  PubMed  CAS  Google Scholar 

  63. Collins P, Rogers S, Goggin M, et al. Cryotherapy of lentigo maligna. Clin Exp Dermatol. 1991; 16: 433–5

    Article  PubMed  CAS  Google Scholar 

  64. Lorenz E. Cryosurgery for lentigo maligna [short communication]. Dermatol Times. 1983; 4: 29

    Google Scholar 

  65. Zacarian SA. Cryosurgery for skin cancer and cutaneous disorders. St Louis (MO): Mosby, 1985: 199–214

    Google Scholar 

  66. Bohler-Sommeregger K, Schuller-Petrovic S, Neumann R, et al. Cryosurgery for lentigo maligna. Plast Reconstr Surg. 1992; 90: 436–40

    Article  PubMed  CAS  Google Scholar 

  67. Dawber RPR, Wilkinson JD. Melanotic freckle of Hutchinson: treatment of macular and nodular phases with cryotherapy. Br J Dermatol. 1979; 101: 47–9

    Article  PubMed  CAS  Google Scholar 

  68. Gage AA, Meenaghan MA, Natiella JR, et al. Sensitivity of pigmented mucosa and skin to freezing injury. Cryobiology. 1979; 16: 348–61

    Article  PubMed  CAS  Google Scholar 

  69. Zacarian SA. Cryosurgical treatment of lentigo maligna. Arch Dermatol. 1982; 118 (2): 89–92

    Article  PubMed  CAS  Google Scholar 

  70. Kuflik EG. Cryosurgery for lentigo maligna: a report of 4 cases. J Dermatol Surg Oncol. 1980; 6 (6): 432–5

    PubMed  CAS  Google Scholar 

  71. Burge SM, Dawber RP. Cryotherapy for lentigo maligna [letter]. J Dermatol Surg Oncol. 1984; 10 (11): 910

    PubMed  CAS  Google Scholar 

  72. Bohler-Sommeregger K, Schuller-Petrovic S, Knobler R, et al. Reactive lentiginous hyperpigmentation after cryosurgery for lentigo maligna. J Am Acad Dermatol. 1992; 27: 523–6

    Article  PubMed  CAS  Google Scholar 

  73. Miescher G. Ober melanotische Prdeancerosen. Oncologia. 1954; 7: 92–4

    Article  PubMed  CAS  Google Scholar 

  74. de Groot WP. Provisional results of treatment of the mélanose précancéreuse circonscrite Dubreuilh by bucky rays. Dermatologica. 1968; 136: 429–31

    Article  PubMed  Google Scholar 

  75. Kopf AW, Bart RS, Gladstein AH. Treatment of melanotic freckle with x-rays. Arch Dermatol. 1976; 112: 801–7

    Article  PubMed  CAS  Google Scholar 

  76. Richter VG, Kleine-Natrop HE. Die Behandlung der melanosis circumscripta praecancerosa mit besonderer berücksichtigung der dermatologischen grenzstrahltherapie. Dermatol Monatsschr. 1977; 163: 195–202

    PubMed  CAS  Google Scholar 

  77. Petratos MA, Kopf AW, Bart RS, et al. Treatment of melanotic freckle with x rays. Arch Dermatol. 1972; 106: 189–94

    Article  PubMed  CAS  Google Scholar 

  78. Storck H. Treatment of melanotic freckles by radiotherapy. J Dermatol Surg Oncol. 1977; 3: 293–4

    PubMed  CAS  Google Scholar 

  79. Arma-Szlachcic M, Ott F, Storck H. Zur Strahlentherapie melanotischen Prdcancerosen. Hautartzt. 1970; 21: 505–8

    CAS  Google Scholar 

  80. Duncuart F, Harwood AR, Fitzpatrick PJ. The radiotherapy of lentigo maligna and lentigo maligna melanoma of the head and neck. Cancer. 1980; 45 (9): 2279–83

    Article  Google Scholar 

  81. Harwood AR. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J Radial Oncol Biol Phys. 1983; 9: 1019–21

    Article  CAS  Google Scholar 

  82. Panizzon RG. Radiotherapy of benign and premalignant skin diseases [abstract]. J Fur Acad Dermatol Venereol. 1997; 9 Suppl. 1: S62

    Article  Google Scholar 

  83. Schmid-Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol. 2000; 43 (3): 477–82

    Article  PubMed  CAS  Google Scholar 

  84. Harwood AR. Conventional radiotherapy in the treatment of lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1982; 6: 310–6

    Article  PubMed  CAS  Google Scholar 

  85. Shaw HC. Lentigo maligna: report of one case treated with radium. Am J Cancer. 1931; 15: 1557–69

    Google Scholar 

  86. Corsi H. Three cases of mélanose circonscrite précancéreuse. Proc R Soc Med. 1938; 32: 261–3

    Google Scholar 

  87. Berridge JK, Morgan DA. A comparison of late cosmetic results following two different radiotherapy techniques for treating basal cell carcinoma. Clin Oncol (R Coll Radiol). 1997; 9 (6): 400–2

    Article  CAS  Google Scholar 

  88. Nazzaro-Porro M, Passi S, Balul L, et al. Effect of dicarboxylic acids on lentigo maligna. J Invest Dermatol. 1979; 72: 296–305

    Article  PubMed  CAS  Google Scholar 

  89. Breathnach AS, Martin B, Nazzaro-Porro M, et al. Effect of dicarboxylic acids on normal human melanocytes in dispersed tissue culture. Br J Dermatol. 1993; 32: 363–4

    Google Scholar 

  90. Nazzaro-Porro M. The use of azelaic acid in hyperpigmentation. Rev Contemp Pharmacother. 1993; 4: 415–23

    Google Scholar 

  91. Liebl H, Stingl G, Pehamberger H, et al. Inhibition of DNA synthesis of melanoma cells by azelaic acid. J Invest Dermatoll. 1984; 85: 417–22

    Article  Google Scholar 

  92. Nazzaro-Porro M, Passi S, Zina G, et al. 10 years experience treating lentigo maligna with topical azelaic acid. Acta Derm Venereol Suppl (Storch). 1989; 143: 49–57

    CAS  Google Scholar 

  93. Nazzaro-Porro M, Passi S, Zinna G, et al. Effect of azelaic acid on human malignant melanoma. Lancet. 1980; I: 1109–11

    Article  Google Scholar 

  94. Breathnach AS, Nazzaro-Porro M, Passi S. Azelaic acid. Br J Dermatol. 1984; 111: 115–20

    Article  PubMed  CAS  Google Scholar 

  95. Prieto MAR, Lopez PM, Gonzalez IR, et al. Treatment of Lentigo Maligna with azelaic acid. Int J Dermatol. 1993; 32 (5): 363–4

    Article  Google Scholar 

  96. Doherty VR. Azelaic acid in lentigo maligna [letter]. Br J Dermatol. 1987; 116: 606

    Article  Google Scholar 

  97. Ertle T, Wiskermann A, Janner M. Local treatment of lentigo maligna with azelaic acid. Arch Dermatol Res. 1981; 271: 197–203

    Article  Google Scholar 

  98. McClean DI, Peter KK. Apparent progression of lentigo maligna to invasive melanoma during treatment with topical azelaic acid. Br J Dermatol. 1986; 114: 685–9

    Article  Google Scholar 

  99. Arndt KA. Argon laser treatment of lentigo maligna. J Am Acad Dermatol. 1984; 10: 953–7

    Article  PubMed  CAS  Google Scholar 

  100. Arndt KA. New pigmented macule appearing 4 years after argon laser treatment of lentigo maligna [letter]. J Am Acad Dermatol. 1986; 14: 1092

    Article  PubMed  CAS  Google Scholar 

  101. Kopera D. Treatment of Lentigo maligna with the carbon dioxide laser. Arch Dermatol. 1995; 131: 735–6

    Article  PubMed  CAS  Google Scholar 

  102. Thissen M, Westerhof W. Lentigo maligna treated with ruby laser[letter]. Acta Derm Venersol. 1997; 77: 163

    CAS  Google Scholar 

  103. Orten SS, Waner M, Dinehart SM, et al. Q switched neodymium: yttriumaluminium-garnet laser treatment of lentigo maligna. Otolaryngol Head Neck Surg. 1999 Mar; 120 (3): 296–302

    Article  PubMed  CAS  Google Scholar 

  104. Iyer S, Goldman M. Treatment of lentigo maligna with combination laser therapy: recurrence at 8 months after initial resolution. J Cosmet Laser Ther. 2003; 5 (1): 49–52

    Google Scholar 

  105. Dorr RT. Interferon-alpha in malignant and viral diseases: a review. Drugs. 1993; 45: 177–211

    Article  PubMed  CAS  Google Scholar 

  106. Punt CJ. The use of interferon-alpha in the treatment of cutaneous melanoma: a review. Melanoma Res. 1998; 8: 95–104

    Article  PubMed  CAS  Google Scholar 

  107. von Wussow P, Block B, Hartmann F, et al. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer. 1988; 61: 1071–4

    Article  Google Scholar 

  108. Comejo P, Vanaclocha F, Polimon I, et al. Intralesional interferon treatment of lentigo maligna. Arch Dermatol. 2000; 136: 428–30

    Article  Google Scholar 

  109. Chanco Turner ML, Moshell AN, Corbet DW, et al. Clearing of melanoma in situ with intralesional interferon alpha in a patient with xeroderma pigmentosum. Arch Dermatol. 1994; 130: 1491–4

    Article  Google Scholar 

  110. Carucci JA. Intralesional interferon alpha for treatment of recurrent lentigo maligna of the eyelid in a patient with primary acquired melanosis. Arch Dermatol. 2000; 136: 1415–6

    Article  PubMed  CAS  Google Scholar 

  111. Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol. 1998; 110: 734–9

    Article  PubMed  CAS  Google Scholar 

  112. Michalopoulos P, Yawalkar N, Bronnimann M, et al. Characterisation of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol. 2004; 151 (4): 903–6

    Article  PubMed  CAS  Google Scholar 

  113. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000; 143: 843–5

    Article  PubMed  CAS  Google Scholar 

  114. Ormond P, Blasdale C, Leonard N, et al. Treatment of lentigo maligna with imiquimod [abstract]. Br J Dermatol. 2002; 147 Suppl. 62: 57

    Google Scholar 

  115. Powell AM, Russell-Jones R. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J Am Acad Dermatol. 2004; 50 (5): 792–6

    Article  PubMed  Google Scholar 

  116. Chapman MS. Histological resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol. 2003; 139: 943–4

    Article  PubMed  Google Scholar 

  117. Epstein E. Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol. 2003; 139: 944–5

    Article  PubMed  Google Scholar 

  118. Fisher GH, Lang PG. Treatment of melanoma in situ on sun damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol. 2003; 139: 943–4

    Article  Google Scholar 

  119. Kamin A, Eigentler TK, Radny P, et al. Imiquimod in the treatment of extensive recurrent lentigo maligna. J Am Acad Dermatol. 2005; 52 (2 Suppl. 1): 51–2

    Article  PubMed  Google Scholar 

  120. Munoz CM, Sanchez JL, Martin-Garcia RF. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg. 2004; 30 (12 Pt 2): 1543–5

    Article  PubMed  Google Scholar 

  121. Kupfer-Bessaguet I, Guillet G, Misery L, et al. Topical imiquimod treatment of lentigo maligna: clinical and histological evaluation. J Am Acad Dermatol. 2004; 51 (4): 635–9

    Article  PubMed  CAS  Google Scholar 

  122. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003; 149 Suppl. 66: 66–70

    Article  PubMed  CAS  Google Scholar 

  123. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol. 2004; 29 (1): 15–21

    Article  PubMed  CAS  Google Scholar 

  124. Fleming CJ, Bryden AM, Evans A, et al. A pilot study of lentigo maligna with 5% imiquimod cream. Br J Dermatol. 2004; 151 (2): 485–8

    Article  PubMed  CAS  Google Scholar 

  125. Ryan RF, Krementz ET, Litwin MS. A role for topical 5-fluorouracil therapy in melanoma. J Surg Oncol. 1988; 33: 250–6

    Article  Google Scholar 

  126. Santos GW. Immunosuppressive drugs. Fed Proc. 1967; 26: 907–13

    PubMed  CAS  Google Scholar 

  127. Nio Y, Imai S, Shiraishi T, et al. Lymphocytes anticancer chemosensitivity testing in vitro: an approach to predict immunosuppressive effect of anticancer agents. Clin Lab Immunol. 1989; 29 (3): 141–5

    CAS  Google Scholar 

  128. Meyskens Jr FL. Modulation of abnormal growth by retinoids: a clinical perspective of the biological phenomena. Life Sci. 1981; 28: 2323–7

    Article  PubMed  CAS  Google Scholar 

  129. Rivers JK, McCarthy WH. No effect of topical tretinoin on lentigo maligna [letter]. Arch Dermatol. 1991; 127: 129

    Article  PubMed  CAS  Google Scholar 

  130. Chimenti S, Carrozzo AM, Citarella L, et al. Treatment of lentigo maligna with tazarotene 0.1% gel. J Am Acad Dermatol. 2004; 50 (1): 101–3

    Article  PubMed  Google Scholar 

  131. Ries LA, Hankey BF, Miller BA, et al. Cancer statistics review 1973–88. NIH Publication #91-2789. Washington (DC): National Cancer Institute, US Government Printing Office, 1991

    Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Department of Dermatology, Walsgrave Hospital, Clifford Bridge Road, Coventry, CV2 2DX, UK

    Olivia Stevenson & Imtiaz Ahmed

Authors
  1. Olivia Stevenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Imtiaz Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olivia Stevenson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stevenson, O., Ahmed, I. Lentigo Maligna. Am J Clin Dermatol 6, 151–164 (2005). https://doi.org/10.2165/00128071-200506030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200506030-00002

Keywords

Search

Navigation